source
- Celldex's barzolvolimab meets Phase 3 goals but safety concerns emergeCelldex announced that its experimental chronic hives treatment, barzolvolimab, achieved the primary endpoint in two Phase 3 trials. The trials demonstrated the drug's efficacy in reducing hive sy…
- Boston life-science lab vacancy climbs to 31% as new spaces sit emptyVacancy rates for laboratory and manufacturing space in Massachusetts have surged dramatically, rising from around 3% in 2021 to roughly 31% by mid-2026, according to recent data. One high-profile…